本文選題：恩諾沙星　切入點(diǎn)：甲氧芐啶　出處：《西北農(nóng)林科技大學(xué)》2015年碩士論文　論文類型：學(xué)位論文

【摘要】：目的:本研究將恩諾沙星(ENR)與乳酸甲氧芐啶(TMP)配伍,通過(guò)體外抗菌活性確定最佳配比,制備出復(fù)方恩諾沙星溶液,并考察其質(zhì)量標(biāo)準(zhǔn)、穩(wěn)定性、體外聯(lián)合抗菌試驗(yàn)以及安全性,為該復(fù)方藥物接下來(lái)的的臨床應(yīng)用積累資料,并提供科學(xué)依據(jù)。方法:(1)研制與質(zhì)量控制:通過(guò)對(duì)多殺性巴氏桿菌、無(wú)乳鏈球菌、金黃色葡萄球菌、大腸埃希菌進(jìn)行體外抑菌試驗(yàn),確定兩種藥物最佳比例及配方;(2)質(zhì)量評(píng)價(jià):通過(guò)雙波長(zhǎng)系數(shù)倍率法計(jì)算得到該復(fù)方溶液劑中恩諾沙星和乳酸甲氧芐啶的含量,并對(duì)該溶液劑進(jìn)行穩(wěn)定性考察;(3)體外聯(lián)合抑菌試驗(yàn):通過(guò)試管肉湯稀釋法測(cè)定兩藥聯(lián)合時(shí)對(duì)四種細(xì)菌的FIC指數(shù),對(duì)聯(lián)合使用效果進(jìn)行考察;(4)安全性評(píng)價(jià):通過(guò)急性毒性試驗(yàn)測(cè)定小鼠經(jīng)口毒性半數(shù)致死量。結(jié)果:(1)研制與質(zhì)量控制:恩諾沙星與乳酸甲氧芐啶的最佳比例為2:1;以蒸餾水作為主要溶劑,加入適量的助溶劑和抗氧化劑,按照工藝流程制出成品,經(jīng)過(guò)質(zhì)量檢查,該制劑的澄明度檢查無(wú)可見(jiàn)異物,pH為5.0-5.2,符合溶液劑的要求;(2)質(zhì)量評(píng)價(jià):建立了藥物含量測(cè)定方法,在286nm及329nm處測(cè)得吸光度,ENR與TMP分別在5-20μg/mL和2.5-10μg/mL范圍內(nèi)線性關(guān)系良好;對(duì)該溶液進(jìn)行高溫和低溫試驗(yàn)、強(qiáng)光照射試驗(yàn)、加速試驗(yàn)進(jìn)行考察,結(jié)果表明強(qiáng)光實(shí)驗(yàn)ENR和TMP含量分別減少7.59%和4.83%,高溫實(shí)驗(yàn)ENR和TMP含量分別減少5.67%和1.40%,低溫試驗(yàn)ENR和TMP含量基本無(wú)變化,加速試驗(yàn)后,ENR和TMP含量各減少5.41%和4.40%;(3)體外聯(lián)合抑菌試驗(yàn):恩諾沙星和乳酸甲氧芐啶聯(lián)合使用,對(duì)多殺性巴氏桿菌、金黃色葡萄球菌表現(xiàn)為協(xié)同作用,對(duì)致病性大腸埃希菌、無(wú)乳鏈球菌表現(xiàn)為相加作用;(4)安全性評(píng)價(jià):該制劑對(duì)小鼠經(jīng)口毒性的LD50為1301.33 mg/kg。結(jié)論:研制出復(fù)方恩諾沙星溶液劑并建立了藥物含量測(cè)定方法;質(zhì)量評(píng)價(jià)符合規(guī)定要求;體外聯(lián)合抑菌試驗(yàn)表明二者聯(lián)合具有正向效應(yīng);半數(shù)致死量試驗(yàn)表明該溶液劑為低毒藥物。
[Abstract]:Objective: to prepare compound enrofloxacin solution with enrofloxacin enrofloxacin (ENR) and trimethoprim lactate (TMPL) by in vitro antibacterial activity, and to investigate its quality standard, stability, in vitro combined antibacterial test and safety. Methods: preparation and quality control of Pasteurella multocida, Streptococcus lactococcus, Staphylococcus aureus, Streptococcus multocida, Staphylococcus aureus. In vitro bacteriostatic test of Escherichia coli was carried out to determine the optimum proportion of the two drugs and the quality evaluation of the formula: the contents of enrofloxacin and trimethoprim lactate in the compound solution were calculated by double wavelength coefficient multiplier method. The stability of the solution was investigated. The combined bacteriostatic test in vitro was carried out. The FIC index of four kinds of bacteria was determined by the broth dilution method. Safety evaluation of the combined use: the lethal dose of oral toxicity in mice was determined by acute toxicity test. Results: development and quality control: the optimum ratio of enrofloxacin and trimethoprim lactate was 2: 1; the optimal ratio of enrofloxacin to trimethoprim lactate was 2: 1; the optimal ratio of enrofloxacin to trimethoprim lactate was 2: 1; Distilled water as the main solvent, Adding appropriate amount of cosolvent and antioxidants, the finished product was produced according to the technological process. After quality inspection, the clarity of the preparation was not detected. The pH value of the preparation was 5.0-5.2, which met the requirements of the solution agent. The quality evaluation was established: a method was established for the determination of the content of the drug. At 286nm and 329nm, the linear relationship between TMP and absorbance was obtained in the range of 5-20 渭 g / mL and 2.5-10 渭 g / mL, respectively. The results showed that the contents of ENR and TMP were decreased by 7.59% and 4.83 respectively, the contents of ENR and TMP were decreased by 5.67% and 1.40 in high temperature experiment, and the contents of ENR and TMP in low temperature test were almost unchanged. In vitro combined bacteriostatic test: Enrofloxacin combined with trimethoprim lactate showed synergistic effect on Pasteurella multocida and Staphylococcus aureus, and on pathogenic Escherichia coli. Safety evaluation of streptococcus lactobacillus: the LD50 of oral toxicity of this preparation to mice was 1301.33 mg / kg. Conclusion: compound enrofloxacin solution was developed and a method for determination of its content was established. The combined bacteriostasis test in vitro showed that the combination had positive effect, and the 50% lethal dose test showed that the solution was a low toxic drug.
【學(xué)位授予單位】：西北農(nóng)林科技大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2015
【分類號(hào)】：S859.79

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 羅雅勁;孫永學(xué);李小娜;曾東平;;恩諾沙星微囊制劑在豬體內(nèi)殘留消除規(guī)律研究[J];中國(guó)畜牧獸醫(yī);2010年02期

2 劉開(kāi)永,汪開(kāi)毓;恩諾沙星在水產(chǎn)中的應(yīng)用與研究[J];中國(guó)獸藥雜志;2004年10期

3 邱宗邦;仔豬恩諾沙星中毒的診療報(bào)告[J];廣西畜牧獸醫(yī);2005年05期

4 陳紅;陳杖榴;曾振靈;梁志立;韋筱涵;;恩諾沙星在雞內(nèi)服和肌肉注射給藥后的排泄研究[J];中國(guó)獸醫(yī)雜志;2005年12期

5 周友中;李銳;林佳潔;朱樹(shù)漢;肖希龍;;恩諾沙星肺靶向微球的研究[J];中國(guó)獸醫(yī)雜志;2006年04期

6 陳仙;陳雙偉;胡建松;;恩諾沙星原料有關(guān)物質(zhì)檢查方法的研究[J];中獸醫(yī)醫(yī)藥雜志;2008年03期

7 楊太;伍東岳;陳永斌;郭允秋;;恩諾沙星可溶性原料制備工藝的研究[J];畜牧獸醫(yī)科技信息;2010年05期

8 張向果;陶s，

本文編號(hào)：1635848